4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid has been researched along with epidermal growth factor in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binder, C; Einspanier, A; Hagemann, T; Husen, B; Schulz, M | 1 |
1 other study(ies) available for 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid and epidermal growth factor
| Article | Year |
|---|---|
Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases.
Topics: Breast Neoplasms; Collagenases; Enzyme Inhibitors; Epidermal Growth Factor; Female; Humans; Hydroxamic Acids; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Oligopeptides; Relaxin; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Tissue Inhibitor of Metalloproteinase-4; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured; Up-Regulation | 2002 |